The Kidney Cancer Diagnostics And Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Kidney Cancer Diagnostics And Therapeutics Market:
According to The Business Research Company’s Kidney Cancer Diagnostics And Therapeutics Global Market Report 2024, The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $3.85 billion in 2023 to $4.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to research on molecular biology, clinical trials and drug development, surgical innovations, genetic discoveries, healthcare access improvements.
The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to biomarker research, genomic sequencing advances, telemedicine and remote consultations, precision medicine advancements, rapid diagnostic technologies. Major trends in the forecast period include palliative care integration, long-term survivorship care, nutrition and lifestyle intervention, expanded role of radiomics, liquid biopsies adoption.
The increasing prevalence of kidney cancer is expected to drive the growth of kidney cancer diagnostics and therapeutics market. Kidney cancer refers to a condition that originates when the normal cells in one or both kidneys undergo abnormal changes and exhibit uncontrolled growth, resulting in the formation of a mass known as a renal cortical tumor. Diagnostics and therapeutics for kidney cancer play a crucial role in the management and treatment of the disease, offering several benefits for patients. offer several benefits in the management of kidney cancer, such as early detection, accurate diagnosis, treatment selection, personalized medicine, and treatment monitoring. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization working for cancer care, in the United States, kidney cancer will be discovered in 81,800 individuals in 2023 (52,360 males and 29,440 women). And in 2020, kidney cancer will have affected 431,288 individuals globally. Therefore, the increasing prevalence of kidney cancer is expected to propel the growth of kidney cancer diagnostics and therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=11937&type=smp
The kidney cancer diagnostics and therapeutics market covered in this report is segmented –
1) By Cancer Type: Clear Cell RCC, Papillary RCC, Chromophobe RCC, Urothelial Carcinoma And Transitional Cell Carcinoma, Other Cancer Types
2) By Component: Drugs, Diagnostics
3) By Diagnostics: Biopsy, CT Scan, Nephro-ureteroscopy, Intravenous Pyelogram, Ultrasound
4) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy
5) By End-Users: Hospitals, Pharmaceutical Labs, Genomics Laboratories
Product approval is a key trend gaining popularity in the kidney cancer diagnostics and therapeutics market. Major companies operating in the kidney cancer diagnostics and therapeutics market are focused on developing innovative products to strengthen their position in the market. For instance, in July 2021, Merck & Co., Inc., a US-based pharmaceutical company, received Health Canada’s approval for KEYTRUDA (pembrolizumab) to treat patients with intermediate-high or substantial risk of recurrence of renal cell carcinoma (RCC) following nephrectomy. KEYTRUDA is a humanized monoclonal antibody that works by blocking the programmed death ligand 1 (PD-L1) protein on tumor cells, which helps keep the immune system from attacking the cancer. Additionally, the immunotherapy KEYTRUDA is the first to be authorized for use in the adjuvant treatment of renal cell carcinoma (RCC). This approval is a significant advance in the treatment of this disease. Also, it can help shrink tumors, slow the growth of cancer, and improve quality of life by reducing symptoms such as pain, fatigue, and nausea.
The kidney cancer diagnostics and therapeutics market report table of contents includes:
- Executive Summary
- Kidney Cancer Diagnostics And Therapeutics Market Characteristics
- Kidney Cancer Diagnostics And Therapeutics Market Trends And Strategies
- Kidney Cancer Diagnostics And Therapeutics Market – Macro Economic Scenario
- Global Kidney Cancer Diagnostics And Therapeutics Market Size and Growth
.
.
.
- Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Benchmarking
- Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Dashboard
- Key Mergers And Acquisitions In The Kidney Cancer Diagnostics And Therapeutics Market
- Kidney Cancer Diagnostics And Therapeutics Market Future Outlook and Potential Analysis
- Appendix
Top Major Players:
- Pfizer Inc
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Bayer AG
- Novartis AG
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
